Mahamaya Lifesciences Ltd
Mahamaya Lifesciences Ltd (MAHALIFE) last reported results for the quarter ended Mar 2026, with sales of ₹166 crore and net profit of ₹8 crore. The stock last traded at ₹178, a market capitalisation of ₹417 crore, on a P/E of 25.2. Over the past 52 weeks the stock has ranged between ₹111 and ₹205. Figures are as of 6 Oct 2026 and are not real time.
Mahamaya Lifesciences Ltd share price and key metrics
- Current price
- ₹178
- Market cap
- ₹417 cr
- Stock P/E
- 25.2
- Book value
- ₹52.1
- ROE
- 19.3%
- ROCE
- 20.0%
- Dividend yield
- 0.00%
- 52w high / low
- 205/111
Metrics as of 6 Oct 2026. Not real time.
Track Mahamaya Lifesciences Ltd
Cruxal reads every Mahamaya Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Mahamaya Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 34%
- TTM
- 24%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 64%
- TTM
- 28%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 23%
- 3 Years
- 24%
- Last Year
- 19%
Mahamaya Lifesciences Ltd quarterly results
| ₹ crore | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 146 | 163 | 166 |
| Expenses | 133 | 148 | 149 |
| Operating profit | 13 | 15 | 17 |
| OPM % | 9% | 9% | 10% |
| Other income | 1 | 1 | 1 |
| Interest | 4 | 4 | 4 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 10 | 11 | 12 |
| Tax % | 27% | 27% | 35% |
| Net profit | 7 | 8 | 8 |
| EPS (₹) | 4.08 | 4.71 | 3.48 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Mahamaya Lifesciences Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 90 | 137 | 161 | 266 | 329 |
| Operating profit | 6 | 9 | 13 | 25 | 34 |
| OPM % | 7% | 6% | 8% | 9% | 10% |
| Net profit | 3 | 4 | 5 | 13 | 17 |
| EPS (₹) | 21.78 | 30.03 | 41.80 | 7.21 | 7.06 |
TTM is the trailing twelve months to the most recent quarter.
Mahamaya Lifesciences Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 18 | 23 |
| Reserves | 14 | 18 | 23 | 32 | 99 |
| Borrowings | 19 | 24 | 55 | 58 | 91 |
| Other liabilities | 21 | 34 | 33 | 81 | 98 |
| Total liabilities | 56 | 78 | 112 | 188 | 310 |
| Fixed assets | 20 | 21 | 21 | 27 | 35 |
| CWIP | 2 | 2 | 3 | 4 | 8 |
| Investments | -0 | -0 | -0 | -0 | -0 |
| Other assets | 34 | 54 | 88 | 157 | 267 |
| Total assets | 56 | 78 | 112 | 188 | 310 |
As reported by the company. Total assets equal total liabilities by construction.
Mahamaya Lifesciences Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 2 | 1 | -23 | -0 | -30 |
| Cash from investing | -3 | -3 | -2 | -7 | -16 |
| Cash from financing | 1 | 2 | 24 | 9 | 81 |
| Net cash flow | 0 | 1 | -0 | 1 | 35 |
| Free cash flow | -1 | -2 | -25 | -5 | -38 |
| CFO / operating profit | 56% | 24% | -162% | 6% | -75% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Mahamaya Lifesciences Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 20% | 21% | 26% | 20% |
| Debtor days | 37 | 25 | 64 | 67 | 78 |
| Inventory days | 93 | 109 | 137 | 167 | 194 |
| Days payable | 83 | 87 | 61 | 92 | 88 |
| Cash conversion cycle | 47 | 48 | 140 | 142 | 184 |
| Working capital days | 8 | 9 | 14 | 29 | 49 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Mahamaya Lifesciences Ltd shareholding pattern
Promoters held 56.35% at Mar 2026, broadly unchanged since Nov 2025. FIIs 4.77% and DIIs 2.52%.
| % held | Nov 2025 | Mar 2026 |
|---|---|---|
| Promoters | 56.35% | 56.35% |
| FIIs | 6.39% | 4.77% |
| DIIs | 4.67% | 2.52% |
| Public | 32.60% | 36.35% |
| No. of shareholders | 1,034 | 584 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Mahamaya Lifesciences Ltd corporate filings
- Mahamaya Lifesciences publishes executive interview in AgroPages India Focus Issue 2026Company Updatelow impact
Cruxal's analysis: The company, with a market cap of approximately 410 crore and current stock price of 178…
Read the full analysis - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018Company Updatelow impact
- Mahamaya Lifesciences Limited announces management changes including reappointment of independent directors and re-designation of key executives, effective from late 2026Company Updatemedium impact
Cruxal's analysis: Mahamaya Lifesciences Limited has disclosed significant management reorganization through…
Read the full analysis - Corporate Voting Results Confirm Requisite Majorities for Key Resolutions at Mahamaya Lifesciences AGMAGM/EGMhigh impact
Cruxal's analysis: Mahamaya Lifesciences Limited has successfully passed all resolutions at its 24th AGM…
Read the full analysis - Mahamaya Lifesciences Limited Announces Proceedings of 24th Annual General Meeting and Key Management Re-designationsAGM/EGMlow impact
Cruxal's analysis: Mahamaya Lifesciences Limited has concluded its 24th Annual General Meeting, where…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Mahamaya Lifesciences Ltd announces completion of dispatch of 24th AGM noticeCompany Updatelow impact
Cruxal's analysis: Mahamaya Lifesciences Ltd has published a newspaper advertisement confirming the…
Read the full analysis - Mahamaya Lifesciences Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Mahamaya Lifesciences Ltd has filed its Annual Report for the financial year 2025-26 as…
Read the full analysis - Mahamaya Lifesciences Announces 24th AGM and Board Restructuring with Significant Remuneration RevisionsAGM/EGMmedium impact
Cruxal's analysis: Mahamaya Lifesciences Limited has scheduled its 24th Annual General Meeting for September…
Read the full analysis - Mahamaya Lifesciences Limited schedules 24th Annual General Meeting for September 29, 2026Company Updatelow impact
Cruxal's analysis: Mahamaya Lifesciences Limited has issued a formal notice for its 24th Annual General…
Read the full analysis - Mahamaya Lifesciences Announces Leadership Succession and Board ReconstitutionCompany Updatemedium impact
Cruxal's analysis: Mahamaya Lifesciences Limited has announced a significant leadership transition effective…
Read the full analysis - Mahamaya Lifesciences Limited releases investor presentation for scheduled investor meetCompany Updatelow impact
Cruxal's analysis: Mahamaya Lifesciences Limited has filed an intimation regarding an investor presentation…
Read the full analysis - Mahamaya Lifesciences intimates schedule for upcoming Analyst / Investor MeetCompany Updatelow impact
Cruxal's analysis: Mahamaya Lifesciences Ltd. has announced the intimation of a schedule for an upcoming…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.